Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q1 2022 Earnings Conference Call May 4, 2022 11:30 AM ET

Company Participants

Brett Monia - Founder, CEO & Director

Elizabeth Hougen - EVP, Finance & CFO

Eugene Schneider - EVP & Chief Clinical Development Officer

Eric Swayze - EVP, Research

Onaiza Cadoret - EVP and Chief Product Strategy & Operations Officer

Conference Call Participants

Yanan Zhu - Wells Fargo Securities

Brendan Smith - Cowen and Company

Luca Issi - RBC Capital Markets

Jessica Fye - JPMorgan Chase & Co.

Mani Foroohar - SVB Leerink

Gary Nachman - BMO Capital Markets

I-Eh Jen - Laidlaw & Company

Myles Minter - William Blair & Company

Joseph Stringer - Needham & Company

Alexander Thompson - Stifel, Nicolaus & Company

Operator

Good morning, and welcome to the Ionis Pharmaceuticals First Quarter 2022 Financial Results Conference Call. As a reminder, this call is being recorded. At this time, I would like to turn the call over to Ms. Julie Tepper, Investor Relations, to lead off the call. Please begin, ma'am.

Unidentified Company Representative

Thank you, Chuck. Before we begin, I encourage everyone to go to the Investors section of the Ionis website to view the press release and related financial tables we will be discussing today including a reconciliation of GAAP to non-GAAP financials. We believe non-GAAP financial results better represent the economics of our business and how we manage our business. We have also posted slides on our website that accompany today's call.

With me this morning are Brett Monia, Chief Executive Officer; Beth Hougen, Chief Financial Officer; and Eugene Schneider, Chief Clinical Development Officer. And joining us for the Q&A portion of the call are Eric Swayze, Executive Vice President of Research; and Onaiza Cadoret, Chief Product Strategy and Operations Officer.

I would like to drive your attention to Slide 3, which contains our forward-looking statements. During this call, we will be making forward-looking and language statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors contained in our SEC filings for additional details.

With that, I'll turn the call over to Brett.

Brett Monia

Thanks, Julie. Good morning, everyone, and thanks for joining us on today's call. This year, we are already off to a very strong start. We continue making excellent progress to building our commercial organization, advancing and expanding our technology in moving towards delivering an abundance of new medicines to the market. This includes the great progress we're making with our near-term commercial opportunities at inotersen, olezarsen and donidalorsen.